Involving personnel with close professional ties to Vanderbilt, IDBiologics was founded to address discovery and development human monoclonal antibodies for the prevention, treatment, and cure of infectious diseases. The firm's innovative fully human monoclonal antibody platform enables rapid discovery and optimization of broad and potent therapeutic molecules. Using this proprietary platform, IDBiologics has accumulated unparalleled breadth in isolating antibodies for infectious diseases, with lead candidate molecules to diverse targets moving forward in development. Indications are that the firm had been initially structured to develop a prevention for Respiratory Syncytial Virus (RSV). In most people, RSV produces simple cold-like symptoms. However, infants and the elderly are at risk for a more severe and dangerous form of the disease. In partnership with Vandebilt and the Dutch biopharmaceutical firm Batavia Biosciences, the ID iologic effort attempted to emulate the human immune system by using monoclonal antibodies to attack RSV, by using the latest information about the virus and the latest technologies in antibody engineering.
